Artigo Acesso aberto Revisado por pares

In Vivo Chemoprotective Activity of Bovine Dialyzable Leukocyte Extract in Mouse Bone Marrow Cells against Damage Induced by 5-Fluorouracil

2016; Hindawi Publishing Corporation; Volume: 2016; Linguagem: Inglês

10.1155/2016/6942321

ISSN

2314-8861

Autores

Erika Evangelina Coronado-Cerda, Moisés Ármides Franco-Molina, Edgar Mendoza-Gamboa, Heriberto Prado-Garcı́a, Lydia Guadalupe Rivera-Morales, Pablo Zapata‐Benavides, María del Carmen Rodríguez‐Salazar, Diana Caballero‐Hernández, Reyes Támez-Guerra, Cristina Rodríguez‐Padilla,

Tópico(s)

Hematopoietic Stem Cell Transplantation

Resumo

Chemotherapy treatments induce a number of side effects, such as leukopenia neutropenia, peripheral erythropenia, and thrombocytopenia, affecting the quality of life for cancer patients. 5-Fluorouracil (5-FU) is wieldy used as myeloablative model in mice. The bovine dialyzable leukocyte extract (bDLE) or IMMUNEPOTENT CRP® (ICRP) is an immunomodulatory compound that has antioxidants and anti-inflammatory effects. In order to investigate the chemoprotection effect of ICRP on bone marrow cells in 5-FU treated mice, total bone marrow (BM) cell count, bone marrow colony forming units-granulocyte/macrophage (CFU-GM), cell cycle, immunophenotypification, ROS/superoxide and Nrf2 by flow cytometry, and histological and hematological analyses were performed. Our results demonstrated that ICRP increased BM cell count and CFU-GM number, arrested BM cells in G0/G1 phase, increased the percentage of leukocyte, granulocytic, and erythroid populations, reduced ROS/superoxide formation and Nrf2 activation, and also improved hematological levels and weight gain in 5-FU treated mice. These results suggest that ICRP has a chemoprotective effect against 5-FU in BM cells that can be used in cancer patients.

Referência(s)